TEVA Earnings Date: Nov 3, 2026 — Teva Pharmaceutical Industries Limited
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is TEVA's next earnings date?
Teva Pharmaceutical Industries Limited (TEVA) is scheduled to report Q3 2026 earnings on Tuesday, November 3, 2026 at 7:00 AM ET (before market open). The consensus estimate is EPS of $0.72 on revenue of $4.25B.
How did TEVA do in its last earnings report?
In its most recent report on Jul 29, 2026 (Q2 2026), Teva Pharmaceutical Industries Limited posted EPS of $0.02 versus the $0.41 estimate, a miss of 95.1%. Revenue was $4.14B against a $4.07B estimate.
How much does TEVA stock move after earnings?
TEVA beat EPS estimates in 6 of its last 8 reported quarters. Over the last 5 reports the stock moved an average of 1.4% (up or down) in the day after earnings.
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | Q2 2026 | 0.41 | 0.02 | -95.12% | $4.14B | ❌ Miss | — | — | — |
| 2026-04-29 | Q1 2026 | 0.46 | 0.53 | +15.22% | $3.98B | ✅ Beat | +0.66% | +2.71% | -0.17% |
| 2026-01-28 | Q4 2025 | 0.63 | 0.96 | +52.38% | $4.71B | ✅ Beat | -0.28% | +5.27% | +1.96% |
| 2025-11-05 | Q3 2025 | 0.67 | 0.78 | +16.42% | $4.48B | ✅ Beat | — | — | — |
| 2025-07-30 | Q2 2025 | 0.61 | 0.66 | +8.20% | $4.20B | ✅ Beat | — | — | — |
| 2025-01-29 | Q4 2024 | 0.70 | 0.71 | +1.43% | $4.23B | ✅ Beat | -3.78% | -7.17% | -11.22% |
| 2024-07-31 | Q2 2024 | 0.55 | 0.61 | +10.91% | $4.16B | ✅ Beat | +0.63% | -3.67% | +8.26% |
| 2024-05-08 | Q1 2024 | 0.51 | 0.48 | -5.88% | $3.82B | ❌ Miss | +1.65% | +6.61% | +6.86% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY26 · $3.98B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 85.1% | $3.39B | -0.2% | $3.79B | $7.00B | $3.40B | $3.64B |
| Distribution Service | 9.9% | $396.0M | +3.1% | $390.0M | $804.0M | $384.0M | $377.0M |
| Product and Service, Other | 3.9% | $157.0M | +106.6% | $102.0M | $157.0M | $76.0M | $117.0M |
| License | 1.0% | $39.0M | +8.3% | $45.0M | $92.0M | $36.0M | $46.0M |
By region
Q1 FY26 · $3.40B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| United States | 45.1% | $1.53B | — | — | — | — | $2.15B |
| Europe | 39.4% | $1.34B | +12.2% | $1.26B | $2.63B | $1.19B | $1.30B |
| International Markets | 15.4% | $524.0M | -10.0% | $613.0M | $1.26B | $582.0M | $495.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.